Newsmaker: Dr. Anette Duensing

| Friday, Sept. 7, 2012, 12:01 a.m.

Dr. Anette Duensing

Noteworthy: Duensing received funding from the GIST Cancer Research Fund — a patient-driven organization that funds research on gastrointestinal stromal tumors, or GISTs. This is the seventh consecutive year that the fund has supported research in Duensing's laboratory.

Age: 43

Residence: O'Hara

Family: Husband, Stefan

Occupation: Assistant professor of pathology, University of Pittsburgh School of Medicine

Background: In 2000, during her postdoctoral fellowship at Brigham and Women's Hospital in Boston, Duensing experienced firsthand the tumor remission of the first GIST patient treated with the therapy drug Gleevec. Since then, her research has focused on a better molecular understanding of the biology of GISTs and the mode of action of Gleevec. Duensing joined the University of Pittsburgh Cancer Institute in 2003.

Education: Medical degree from the University of Hannover Medical School, Hannover, Germany, in 1997

Quote: “This generous funding has allowed us to significantly expand our efforts identifying novel treatment options for GIST patients — in particular for patients whose tumors have become resistant to Gleevec over time.”

— Chris Togneri

Subscribe today! Click here for our subscription offers.


Show commenting policy